Precise execution

MC Services is...

Client News

… an international Corporate Communications and Investor Relations firm providing high-level consultancy with targeted services and support for transaction-oriented assignments throughout Europe and the United States.

read more

MC Services at analytica in Munich on April 03, 2014 (FINANCE DAY)

MC Services, the international Investor Relations and Public Relations Company, hosted a booth at this year’s analytica meeting, the leading trade fair for modern laboratory technology and biotechnology. Our focus this year was on the FINANCE DAY on April 03, 2014, in which also some of our clients participated in panel sessions.

read more

MC Services one of the main sponsors of the 7th DVFA Life Science Conference 2014

This year MC Services acted as one of the main sponsors of the 7th DVFA Life Science Conference, which took place in Frankfurt on May 07, 2014. Over recent years the DVFA Life Science Conference has become a highly valued platform to discuss new innovative technologies, therapies and products with financial market participants.

The conference focused on innovative treatment strategies for cancer, an area where MC Services’ clients have taken leading roles.

read more



Transgene Announces Third Quarter 2014 Financial Results


ERYTECH announces granting of new patent in the United States


4SC further strengthens patent protection for its lead compound resminostat


MorphoSys Announces Clinical Milestone in Ophthalmology Program


Epigenomics AG raises USD 5.3 million from its strategic commercialization partner BioChain


Medigene announces publication in Cancer Immunology, Immunotherapy on DC vaccine development for a Phase I/II trial in acute myeloid leukemia


Sucessful Spin-Out of ImevaX GmbH from the Technische Universität München (TUM) and funding by the Federal Ministry of Education and Research (BMBF) with EURO 5.9 million


WILEX publishes 9-month Financial Report 2014



MorphoSys Acquires Lanthipeptide Technology from Lanthio Pharma


WILEX subsidiary Heidelberg Pharma extends research collaboration with Roche